1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Infectious Disease Treatment Market
2.2. Global Infectious Disease Treatment Market, By Therapeutics, 2023 (US$ Million)
2.3. Global Infectious Disease Treatment Market, By Application, 2023 (US$ Million)
2.4. Global Infectious Disease Treatment Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Infectious Disease Treatment Market: Competitive Analysis
3.1. Market Positioning of Key Infectious Disease Treatment Market Vendors
3.2. Strategies Adopted by Infectious Disease Treatment Market Vendors
3.3. Key Industry Strategies
4. Infectious Disease Treatment Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Infectious Disease Treatment Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Antibacterial drugs
5.3.2. Antiviral drugs
5.3.3. Antifungal drugs
5.3.4. Antiparasitic drugs
5.3.5. Projected sales of Phase III drugs estimated till 2029 (US $ Mn)
5.3.5.1. Imipenem/Cilastatin + relebactum
5.3.5.2. Cadazolid
5.3.5.3. GS-9620 (TLR-7 Agonist)
5.3.5.4. Doravirine (MK-1439)
5.3.5.5. Others
5.3.6. Tabular representation of Phase II and I drugs

6. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Acquired Immune Deficiency Syndrome (AIDS)
6.3.2. Hepatitis B
6.3.3. Hepatitis C
6.3.4. Human Papillomavirus
6.3.5. Hospital acquired Methicillin-resistant Staphylococcus aureus infection (MRSA)
6.3.6. Chlamydia trachomatis and Neisseria Gonorrhea (CT/NG)
6.3.7. Others


7. North America Infectious Disease Treatment Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
7.3. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
7.4.Infectious Disease Treatment Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
7.4.1.1.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
7.4.1.2.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
7.4.1.3.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)

8. UK and European Union Infectious Disease Treatment Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.3. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
8.4.Infectious Disease Treatment Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.4.1.1.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.4.1.2.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.4.1.3.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.4.1.4.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.4.1.5.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
8.4.1.6.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)

9. Asia Pacific Infectious Disease Treatment Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.3. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
9.4.Infectious Disease Treatment Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.4.1.1.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.4.1.2.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.4.1.3.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.4.1.4.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.4.1.5.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
9.4.1.6.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)

10. Latin America Infectious Disease Treatment Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
10.3. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
10.4.Infectious Disease Treatment Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
10.4.1.1.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
10.4.1.2.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
10.4.1.3.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)

11. Middle East and Africa Infectious Disease Treatment Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
11.3. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
11.4.Infectious Disease Treatment Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
11.4.1.1.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
11.4.1.2.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Infectious Disease Treatment Market: By Therapeutics, 2022-2032, USD (Million)
11.4.1.3.2. Infectious Disease Treatment Market: By Application, 2022-2032, USD (Million)

12. Company Profile
12.1. Pfizer, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. F.Hoffman-La Roche AG
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Abbott Laboratories
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Abbvie, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Merck & Company
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Alere, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Allergan, Inc.
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Bayer AG
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Baxter International Inc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Bristol-Myers Squibb Company
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Actelion Pharmaceuticals Ltd.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives
12.12. Gilead Sciences, Inc.
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Portfolio
12.12.4. Strategic Initiatives